Member access

4-Traders Homepage  >  Shares  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)

306
Real-time Quote. Real-time Tradegate - 01/28 01:12:50 pm
70.265 EUR   +0.36%
01/12 UCB : Update of transparency notification UCB SA/NV
01/09 DERMIRA : and UCB announce start of Phase 3 program for CIMZIA (cert..
01/07 UCB : Acquisition of own shares
 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
01/21/2015 01/22/2015 01/23/2015 01/27/2015 01/28/2015 Date
69.31(c) 68.33(c) 69.99(c) 70.01(c) 70.21 Last
347 925 336 177 375 451 184 339 159 461 Volume
-0.57% -1.41% +2.43% +0.03% +0.29% Change
More quotes
Company
UCB SA is a biopharmaceutical company that engages in the research, development and commercialization of innovative drugs in the fields of central nervous system and immunology disorders.It focuses on the discovery and development of innovative medicines and solutions to transform the lives of... 
Sector
Pharmaceuticals
Calendar
02/25Earnings Release
More about the company
Surperformance© ratings of UCB
Trading Rating : Investor Rating :
More Ratings
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Full-screen chart
Financials (€)
Sales 2014 3 398 M
EBIT 2014 452 M
Net income 2014 241 M
Debt 2014 1 335 M
Yield 2014 1,52%
Sales 2015 3 660 M
EBIT 2015 582 M
Net income 2015 343 M
Debt 2015 1 168 M
Yield 2015 1,70%
PER 2014 55,56
PER 2015 37,68
EV / Sales 2014 4,40x
EV / Sales 2015 4,04x
Capitalization 13 617 M
More Financials
Latest news on UCB
01/12 UCB : Update of transparency notification UCB SA/NV
01/09 DERMIRA : and UCB announce start of Phase 3 program for CIMZIA (certolizumab peg..
01/07 UCB : Acquisition of own shares
2014 UCB : Selects Cegedim Relationship Management Mobile Intelligence Cloud Platform
2014 UCB : "Method for Producing Protein" in Patent Application Approval Process
2014DJUCB : Advent, Avista End Acquisition Agreement
2014 UCB : Taps Cegedim Relationship Management Mobile Intelligence Cloud Platform
2014 UCB : Transparency notification of Vanguard Health Care Fund
More news
Sector news Biopharmaceuticals
12:49p US markets plunge after top firms post poor results
12:46pDJEU Approves Three-Part Deal Between Novartis, GlaxoSmithKline
12:33p GLAXOSMITHKLINE : EU Approves Novartis-Glaxo Business Swap, With Concessions
Plus d'actualités du secteur Biopharmaceuticals


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF